Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
ENIGMA Clinical High Risk for Psychosis Working Group,Shalaila S Haas,Ruiyang Ge,Ingrid Agartz,G Paul Amminger,Ole A Andreassen,Peter Bachman,Inmaculada Baeza,Sunah Choi,Tiziano Colibazzi,Vanessa L Cropley,Camilo de la Fuente-Sandoval,Bjørn H Ebdrup,Adriana Fortea,Paolo Fusar-Poli,Birte Yding Glenthøj,Louise Birkedal Glenthøj,Kristen M Haut,Rebecca A Hayes,Karsten Heekeren,Christine I Hooker,Wu Jeong Hwang,Neda Jahanshad,Michael Kaess,Kiyoto Kasai,Naoyuki Katagiri,Minah Kim,Jochen Kindler,Shinsuke Koike,Tina D Kristensen,Jun Soo Kwon,Stephen M Lawrie,Irina Lebedeva,Jimmy Lee,Imke L J Lemmers-Jansen,Ashleigh Lin,Xiaoqian Ma,Daniel H Mathalon,Philip McGuire,Chantal Michel,Romina Mizrahi,Masafumi Mizuno,Paul Møller,Ricardo Mora-Durán,Barnaby Nelson,Takahiro Nemoto,Merete Nordentoft,Dorte Nordholm,Maria A Omelchenko,Christos Pantelis,Jose C Pariente,Jayachandra M Raghava,Francisco Reyes-Madrigal,Jan I Røssberg,Wulf Rössler,Dean F Salisbury,Daiki Sasabayashi,Ulrich Schall,Lukasz Smigielski,Gisela Sugranyes,Michio Suzuki,Tsutomu Takahashi,Christian K Tamnes,Anastasia Theodoridou,Sophia I Thomopoulos,Paul M Thompson,Alexander S Tomyshev,Peter J Uhlhaas,Tor G Værnes,Therese A M J van Amelsvoort,Theo G M van Erp,James A Waltz,Christina Wenneberg,Lars T Westlye,Stephen J Wood,Juan H Zhou,Dennis Hernaus,Maria Jalbrzikowski,René S Kahn,Cheryl M Corcoran,Sophia Frangou,Paul Allen,Helen Baldwin,Cali F Bartholomeusz,Michael Wl Chee,Xiaogang Chen,Rebecca E Cooper,Lieuwe de Haan,Holly K Hamilton,Ying He,Wenche Ten Velden Hegelstad,Leslie E Horton,Daniela Hubl,Mallory J Klaunig,Alex Koppel,Yoo Bin Kwak,Pablo León-Ortiz,Rachel L Loewy,Patrick McGorry,Lijun Ouyang,Paul E Rasser,Franz Resch,Jason Schiffman,Mikkel E Sørensen,Jinsong Tang,Dennis Velakoulis,Sophia Vinogradov,Hidenori Yamasue,Liu Yuan,Alison R Yung
DOI: https://doi.org/10.1001/jamapsychiatry.2023.3850
2024-01-01
JAMA Psychiatry
Abstract:Importance: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. Objective: To quantify deviations from the normative range of neuroanatomical variation in individuals at clinical high risk for psychosis (CHR-P) and evaluate their overlap with healthy variation and their association with positive symptoms, cognition, and conversion to a psychotic disorder. Design, setting, and participants: This case-control study used clinical-, IQ-, and neuroimaging software (FreeSurfer)-derived regional measures of cortical thickness (CT), cortical surface area (SA), and subcortical volume (SV) from 1340 individuals with CHR-P and 1237 healthy individuals pooled from 29 international sites participating in the Enhancing Neuroimaging Genetics Through Meta-analysis (ENIGMA) Clinical High Risk for Psychosis Working Group. Healthy individuals and individuals with CHR-P were matched on age and sex within each recruitment site. Data were analyzed between September 1, 2021, and November 30, 2022. Main outcomes and measures: For each regional morphometric measure, deviation scores were computed as z scores indexing the degree of deviation from their normative means from a healthy reference population. Average deviation scores (ADS) were also calculated for regional CT, SA, and SV measures and globally across all measures. Regression analyses quantified the association of deviation scores with clinical severity and cognition, and 2-proportion z tests identified case-control differences in the proportion of individuals with infranormal (z < -1.96) or supranormal (z > 1.96) scores. Results: Among 1340 individuals with CHR-P, 709 (52.91%) were male, and the mean (SD) age was 20.75 (4.74) years. Among 1237 healthy individuals, 684 (55.30%) were male, and the mean (SD) age was 22.32 (4.95) years. Individuals with CHR-P and healthy individuals overlapped in the distributions of the observed values, regional z scores, and all ADS values. For any given region, the proportion of individuals with CHR-P who had infranormal or supranormal values was low (up to 153 individuals [<11.42%]) and similar to that of healthy individuals (<115 individuals [<9.30%]). Individuals with CHR-P who converted to a psychotic disorder had a higher percentage of infranormal values in temporal regions compared with those who did not convert (7.01% vs 1.38%) and healthy individuals (5.10% vs 0.89%). In the CHR-P group, only the ADS SA was associated with positive symptoms (β = -0.08; 95% CI, -0.13 to -0.02; P = .02 for false discovery rate) and IQ (β = 0.09; 95% CI, 0.02-0.15; P = .02 for false discovery rate). Conclusions and relevance: In this case-control study, findings suggest that macroscale neuromorphometric measures may not provide an adequate explanation of psychosis risk.